Structure-based Design, Synthesis, And Evaluation of a New Bcl-2/Mcl-1 Inhibitor
DOI:
https://doi.org/10.54097/fywa0t44Keywords:
Apoptosis, Bcl-2/Mcl-1 protein, InhibitorAbstract
Based on our previously reported Bcl-2/Mcl-1 dual inhibitor S1, we designed a new Bcl-2/Mcl-1 inhibitor through a structure-based scaffold-hopping approach, replacing the 6-thiomorpholine of S1 by piperazine group for P2 occupation. Compound S1-11 was synthesized readily by nucleophilic substitution reaction between 1-oxo-1H-phenalene-2,3-dicarbonitrile (OPD) with piperazine, and exhibited potent binding capability to both Bcl-2 (Ki=0.82 ± 0.06 μM) and Mcl-1 (Ki=0.43 ± 0.01 μM). Furthermore, S1-11 exhibited potent lethality on MCF-7 cells.
Downloads
References
[1] A. Abou Samra, A. Robert, C. Gov, L. Favre, L. Eloy, E. Jacquet, J. Bignon, J. Wiels, S. Desrat, F. Roussi, Eur. J. Med. Chem. 2018, 148, pp. 26.
[2] P. E. Czabotar, G. Lessene, A. Strasser, J. M. Adams, Nat. Rev. Mol. Cell Biol. 2014, 15, pp. 49.
[3] C. Chen, Y. Nie, G. Xu, X. Yang, H. Fang, X. Hou, Bioorg. Med. Chem. 2019, 27, pp. 2771.
[4] D. M. Moujalled, G. Pomilio, C. Ghiurau, A. Ivey, J. Salmon, S. Rijal, S. Macraild, L. Zhang, T.‐C. Teh, I.‐S. Tiong, P. Lan, M. Chanrion, A. Claperon, F. Rocchetti, A. Zichi, L. Kraus‐Berthier, Y. Wang, E. Halilovic, E. Morris, F. Colland, D. Segal, D. Huang, A. W. Roberts, A. L. Maragno, G. Lessene, O. Geneste, A.H. Wei, Leukemia 2019, 33, pp. 905.
[5] C. Correia, S. H. Lee, X. W. Meng, N. D. Vincelette, K. L. B. Knorr, H. Ding, G. S. Nowakowski, H. Dai, S. H. Kaufmann, BBA‐Mol. Cell Res. 2015, 1853, pp. 1658.
[6] S. Cory, A. W. Roberts, P. M. Colman, J. M. Adams, Trends Cancer 2016, 2, pp. 443.
[7] R. Liu, L. Liu, X. Yang, H. Fang, Bioorg. Chem. 2019, 88, pp. 102938.
[8] A. Ashkenazi, W.J. Fairbrother, J.D. Leverson, et al., From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors, Nat. Rev. Drug Discov. 2017,16, pp. 273-284.
[9] A.R.D. Delbridge, A. Strasser, The BCL-2 protein family, BH3-mimetics and cancer therapy, Cell Death Differ. 2015, 22, pp. 1071-1080.
[10] J.D. Leverson, H. Zhang, J. Chen, et al., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death Dis. 2015, 6, pp. 1590.
[11] L. Bai, J. Chen, D. McEachern, et al., BM-1197: a novel and specific Bcl-2/Bcl-xl inhibitor inducing complete and long-lasting tumor regression in vivo, PLoS One 2014, 9, pp. e99404.
[12] A.J. Souers, J.D. Leverson, E.R. Boghaert, et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med. 2013, 19, pp. 202-208.
[13] E. Varin, C. Denoyelle, E. Brotin, et al., Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy, Carcinogenesis 2010, 31, pp. 984-993.
[14] Z. Zhang, T. Song, T. Zhang, J. Gao, G. Wu, L. An, G. Du, Int. J. Cancer, 2011, 128, pp. 1724.
[15] Z. Zhang, G. Wu, F. Xie, T. Song, X. Chang, J. Med. Chem. 2011, 54, pp. 1101.
[16] T. Song, X. Li, X. Chang, X. Liang, Y. Zhao, G. Wu, S. Xie, P. Su, Z. Wu, Y. Feng, Z. Zhang, Bioorg. Med. Chem. 2013, 21, pp. 11.
[17] Z. Zhang, P. Su, X. Li, T. Song, G. Chai, X. Yu, K. Zhang, Arch. Pharm. 2015, 348, pp. 89.
[18] J. Cheng, T.J. Deming, Pept. Mater. 2011, 310, pp.1–26.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
